Market Research Logo

Delcath Systems Inc (DCTH) - Financial and Strategic SWOT Analysis Review

Delcath Systems Inc (DCTH) - Financial and Strategic SWOT Analysis Review

- SWOT Analysis Review provides you an provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Delcath Systems Inc (Delcath) specializes in developing percutaneous perfusion technologies to treat primary and metastatic liver cancers. Its patented drug delivery platform delivers ultra-high doses of anti-cancer drugs to the liver, while preventing them from entering the patient's bloodstream. The company develops formulations for use with its proprietary Delcath Hepatic Delivery System (Melphalan/HDS) and to administer high dose chemotherapy to the liver. The company sells its proprietary system to deliver and filter melphalan hydrochloride in Europe under the trade name, Delcath Hepatic Chemosat Delivery System for Melphalan (Chemosat). Delcath is headquartered in New York, the US.

Delcath Systems Inc Key Recent Developments

Jul 29,2019: Delcath enhances Board of Directors With appointment of commercial leader, John R. Sylvester
Nov 13,2018: Delcath announces third quarter fiscal 2018 financial results
Oct 15,2018: Delcath expands rollout of registration trial in metastatic ocular melanoma
Aug 15,2018: Delcath announces second quarter fiscal 2018 financial results
May 10,2018: Delcath Announces First Quarter 2018 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Delcath Systems Inc - Key Facts
Delcath Systems Inc - Key Employees
Delcath Systems Inc - Key Employee Biographies
Delcath Systems Inc - Major Products and Services
Delcath Systems Inc - History
Delcath Systems Inc - Company Statement
Delcath Systems Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Delcath Systems Inc - Business Description
R&D Overview
Delcath Systems Inc - SWOT Analysis
SWOT Analysis - Overview
Delcath Systems Inc - Strengths
Delcath Systems Inc - Weaknesses
Delcath Systems Inc - Opportunities
Delcath Systems Inc - Threats
Delcath Systems Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Delcath Systems Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jul 29, 2019: Delcath enhances Board of Directors With appointment of commercial leader, John R. Sylvester
Nov 13, 2018: Delcath announces third quarter fiscal 2018 financial results
Oct 15, 2018: Delcath expands rollout of registration trial in metastatic ocular melanoma
Aug 15, 2018: Delcath announces second quarter fiscal 2018 financial results
May 10, 2018: Delcath Announces First Quarter 2018 Financial Results
Mar 16, 2018: Delcath Announces 2017 Financial Results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Delcath Systems Inc, Key Facts
Delcath Systems Inc, Key Employees
Delcath Systems Inc, Key Employee Biographies
Delcath Systems Inc, Major Products and Services
Delcath Systems Inc, History
Delcath Systems Inc, Other Locations
Delcath Systems Inc, Subsidiaries
Delcath Systems Inc, Key Competitors
Delcath Systems Inc, Ratios based on current share price
Delcath Systems Inc, Annual Ratios
Delcath Systems Inc, Annual Ratios (Cont...1)
Delcath Systems Inc, Interim Ratios
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Delcath Systems Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Delcath Systems Inc, Performance Chart (2014 - 2018)
Delcath Systems Inc, Ratio Charts
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook